North America holds a dominant share of the Gallium-68 Market, driven by strong healthcare infrastructure, increasing utilization of PET imaging technologies, and expanding nuclear medicine capabilities. The region benefits from rising cancer incidence, robust radiopharmaceutical supply chains, and significant investments in molecular imaging research. The growing adoption of precision medicine...